In the Phase 1b/2 trial, zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, demonstrated clinically meaningful responses in patients with previously treated advanced extrapulmonary neuroendocrine carcinomas (epNECs), with a confirmed objective response rate (ORR) of 40.0% and a median duration of response (mDOR) of 5.6 months
Results indicate responses to zoci monotherapy treatment among multiple epNEC subtypes, including gastroenteropancreatic NEC (GEP-NEC) and other epNEC subgroups, with confirmed ORRs of 35.9% and 47.6%, respectively; deepening anti-tumor activity was observed over time
Zoci demonstrated a manageable safety profile, with a treatment-related discontinuation rate of less than 1%, no treatment-related deaths, and a low rate of interstitial lung disease (ILD)/pneumonitis (1.5%, 2 cases, both Grade 2)
Zai will pursue a potential accelerated approval pathway for zoci in previously treated advanced epNECs based on results from Phase 1/2 trial, with topline data of the full epNEC population expected in 2027
Global Phase 3 first-line maintenance trial of zoci monotherapy in epNECs expected to initiate in 2027

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.